



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 23, 2022

Adam Simpson
Chief Executive Officer
Icosavax, Inc.
1930 Boren Avenue, Suite 1000
Seattle, WA 98101

Re: Icosavax, Inc.
Registration Statement on Form S-3
Filed August 16, 2022
File No. 333-266894

Dear Mr. Simpson:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Cheston Larson, Esq.